Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography

被引:33
作者
Dhananjeyan, Mugunthu R.
Liu, Jidong
Bykowski, Crystal
Trendel, Jill A.
Sarver, Jeffrey G.
Ando, Howard
Erhardt, Paul W.
机构
[1] Univ Toledo, Ctr Drug Design & Dev, Toledo, OH 43606 USA
[2] Pfizer Global Res & Dev, Ann Arbor Labs, Ann Arbor, MI 48105 USA
关键词
5 '-DFCR; 5 '-DFUR; 5-FU; capecitabine; metabolites; prodrugs; Xeloda;
D O I
10.1016/j.chroma.2006.10.038
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A rapid high-performance liquid chromatography method has been developed for simultaneous determination of capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR) and 5-fluorouracil (5-FU). 5'-DFCR was synthesized by hydrolyzing capecitabine using commercially available carboxyl esterase (CES) and characterized by NMR, mass spectrometry and elemental analysis. Baseline separations between capecitabine, 5'-DFCR, 5'-DFUR and 5-FU were found with symmetrical peak shapes on a Discovery RP-amide C-16 column using 10 mM ammonium acetate at pH 4.0 and methanol as the mobile phase. The retention times of capecitabine, 5'-DFCR. 5'-DFUR and 5-FU were 8.9, 5.0. 5.3 and 3.0 min, respectively. Linear calibration curves were obtained for each compound across a range from 1 to 500 mu g ml(-1). The intra- and inter-day relative standard deviations (%RSD) were < 5%. A single-step protein precipitation method was employed for separation of the analytes from bio-matrices. Greater than 85% recoveries were obtained for capecitabine, 5-DFCR, 5'-DFUR and 5-FU from bio-fluids including mouse plasma, mouse serum and rabbit bile. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:101 / 108
页数:8
相关论文
共 20 条
[1]   New systemic frontline treatment for metastatic colorectal carcinoma [J].
Braun, AH ;
Achterrath, W ;
Wilke, H ;
Vanhoefer, U ;
Harstrick, A ;
Preusser, P .
CANCER, 2004, 100 (08) :1558-1577
[2]   Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients [J].
Cassidy, J ;
Twelves, C ;
Cameron, D ;
Steward, W ;
O'Byrne, K ;
Jodrell, D ;
Banken, L ;
Goggin, T ;
Jones, D ;
Roos, B ;
Bush, E ;
Weidekamm, E ;
Reigner, B .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (06) :453-460
[3]   Metabolism of capecitabine, an oral fluorouracil prodrug:: 19F NMR studies in animal models and human urine [J].
Desmoulin, F ;
Gilard, V ;
Malet-Martino, M ;
Martino, R .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (11) :1221-1229
[4]   CLINICAL-PHARMACOLOGY OF 5-FLUOROURACIL [J].
DIASIO, RB ;
HARRIS, BE .
CLINICAL PHARMACOKINETICS, 1989, 16 (04) :215-237
[5]   Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies [J].
Guichard, SM ;
Mayer, I ;
Jodrell, DI .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 826 (1-2) :232-237
[6]  
International Conference on Harmonization (ICH), 2001, GUID BIOAN METH VAL
[7]  
Ishikawa T, 1998, CANCER RES, V58, P685
[8]   A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug [J].
Judson, IR ;
Beale, PJ ;
Trigo, JM ;
Aherne, W ;
Crompton, T ;
Jones, D ;
Bush, E ;
Reigner, B .
INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) :49-56
[9]   Resistance to 5-fluorouracil [J].
Mader, RM ;
Müller, M ;
Steger, GG .
GENERAL PHARMACOLOGY, 1998, 31 (05) :661-666
[10]   Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review [J].
Malet-Martino, M ;
Martino, R .
ONCOLOGIST, 2002, 7 (04) :288-323